Pharmaceutical Lenalidomide for Anti Cancer CAS 191732-72-6
|10-19 20-49 50+|
|FOB Unit Price:||US $1 US $0.8 US $0.5|
|Purchase Qty. (Gram)||FOB Unit Price|
|Port:||Hong Kong, Hong Kong|
|Payment Terms:||T/T, Western Union, Money Gram, Bitcoin|
- Model NO.: CAS 191732-72-6
- Customized: Customized
- Suitable for: Adult
- Purity: >99%
- CAS: 191732-72-6
- MW: 259.2606
- Transport Package: as Requires
- Origin: China
- Powder: No
- Certification: GMP, HSE, ISO 9001, USP, BP
- State: Liquid
- Product Name: Lenalidomide
- Mf: C13h13n3o3
- Trademark: Biopharmchem
- Specification: Pharmaceutical Grade
- HS Code: 2933790090
pharmaceutical Lenalidomide for anti cancer CAS 191732-72-6
Lenalidomide (trade name Revlimid) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Along with several other drugs developed in recent years, lenalidomide has significantly improved overall survival in myeloma (which formerly carried a poor prognosis), although toxicity remains an issue for users.
Multiple myeloma is a cancer of the blood, characterized by accumulation of a plasma cell clone in the bone marrow.Lenalidomide is one of the novel drug agents used to treat multiple myeloma. It is a more potent molecular analog of thalidomide, which inhibits tumor angiogenesis, tumor secreted cytokines and tumor proliferation through the induction of apoptosis.Compared to placebo, lenalidomide is effective at inducing a complete or "very good partial" response as well as improving progression-free survival. Adverse events more common in people receiving lenalidomide for myeloma were neutropenia (a decrease in the white blood cell count), deep vein thrombosis, infections, and an increased risk of other hematological malignancies.The risk of second primary hematological malignancies does not outweigh the benefit of using lenalidomide in relapsed or refractory multiple myeloma.It may be more difficult to mobilize stem cells for autograft in people who have received lenalidomide.
Lenalidomide is undergoing clinical trial as a treatment for Hodgkin's lymphoma,as well as non-Hodgkin's lymphoma, chronic lymphocytic leukemia and solid tumor cancers, such as carcinoma of the pancreas.One Phase 3 clinical trial being conducted by Celgene in elderly patients with B-cell chronic lymphocytic leukemia was halted in July 2013 when a disproportionate number of cancer deaths were observed during treatment with lenalidomide versus patients treated with chlorambucil.
Lenalidomide is related to thalidomide which is known to be teratogenic. Tests in monkeys have suggested lenalidomide is also teratogenic.It therefore has the pregnancy category X and cannot be prescribed for women who are pregnant or who might be conceiving. For this reason, the drug is only available in the United States (under the name Revlimid) through a restricted distribution system called RevAssist.
Other potential side effects are thrombosis, pulmonary embolus, and hepatotoxicity, as well as bone marrow toxicity resulting in neutropenia and thrombocytopenia. Myelosuppression is the major dose-limiting toxicity, which is contrary to experience with thalidomide.
lenalidomide has three main activities: direct anti-tumor effect, inhibition of angiogenesis, and immunomodulation.